NASDAQ:GTBP GT Biopharma (GTBP) Stock Price, News & Analysis $1.83 +0.09 (+5.17%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.91 +0.08 (+4.32%) As of 08/7/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GT Biopharma Stock (NASDAQ:GTBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GT Biopharma alerts:Sign Up Key Stats Today's Range$1.68▼$1.8350-Day Range$1.74▼$3.8052-Week Range$1.68▼$4.10Volume32,802 shsAverage Volume75,331 shsMarket Capitalization$5.98 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingStrong Buy Company Overview GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California. Read More GT Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreGTBP MarketRank™: GT Biopharma scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingGT Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGT Biopharma has received no research coverage in the past 90 days.Read more about GT Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GT Biopharma are expected to grow in the coming year, from ($6.79) to ($2.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GT Biopharma is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GT Biopharma is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about GT Biopharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.17% of the float of GT Biopharma has been sold short.Short Interest Ratio / Days to CoverGT Biopharma has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GT Biopharma has recently decreased by 11.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGT Biopharma does not currently pay a dividend.Dividend GrowthGT Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.17% of the float of GT Biopharma has been sold short.Short Interest Ratio / Days to CoverGT Biopharma has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GT Biopharma has recently decreased by 11.40%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A MarketBeat FollowsOnly 1 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GT Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.40% of the stock of GT Biopharma is held by insiders.Percentage Held by InstitutionsOnly 8.15% of the stock of GT Biopharma is held by institutions.Read more about GT Biopharma's insider trading history. Receive GTBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address GTBP Stock News HeadlinesGT Biopharma, Inc. (GTBP) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comGTBP GT Biopharma, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.August 8 at 2:00 AM | Priority Gold (Ad)GT Biopharma, Inc. Appoints David C. Mun-Gavin to Board of DirectorsJune 15, 2025 | nasdaq.comGT Biopharma Appoints New Member to its Board of DirectorsJune 13, 2025 | globenewswire.comStocks in play: GT Biopharma, Inc.May 19, 2025 | ca.finance.yahoo.comThis Natural Killer Treatment Could Help Transform How Cancer is TreatedMay 19, 2025 | baystreet.caGT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation SignalsMay 19, 2025 | globenewswire.comSee More Headlines GTBP Stock Analysis - Frequently Asked Questions How have GTBP shares performed this year? GT Biopharma's stock was trading at $3.05 at the start of the year. Since then, GTBP shares have decreased by 40.0% and is now trading at $1.83. How were GT Biopharma's earnings last quarter? GT Biopharma, Inc. (NASDAQ:GTBP) issued its quarterly earnings results on Thursday, May, 15th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.12. When did GT Biopharma's stock split? GT Biopharma's stock reverse split on Monday, February 5th 2024.The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GT Biopharma's major shareholders? Top institutional shareholders of GT Biopharma include Bank of Montreal Can (2.83%). Insiders that own company stock include Michael Martin Breen and Manu Ohri. View institutional ownership trends. How do I buy shares of GT Biopharma? Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GT Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC). Company Calendar Last Earnings5/15/2025Today8/08/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GTBP Previous SymbolOTCMKTS:OXISD CIK109657 Webwww.gtbiopharma.com Phone(415) 919-4040FaxN/AEmployees8Year Founded1965Price Target and Rating Average Price Target for GT Biopharma$11.00 High Price Target$11.00 Low Price Target$11.00 Potential Upside/Downside+501.1%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($5.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,033.08% Return on Assets-223.20% Debt Debt-to-Equity RatioN/A Current Ratio0.73 Quick Ratio0.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.75) per share Price / Book-2.44Miscellaneous Outstanding Shares3,270,000Free Float3,162,000Market Cap$5.98 million OptionableNo Data Beta1.33 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:GTBP) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.